Leerink Partners Downgrades Amicus Therapeutics to Market Perform, Lowers Price Target to $14.5

Benzinga · 1d ago
Leerink Partners analyst Joseph Schwartz downgrades Amicus Therapeutics (NASDAQ:FOLD) from Outperform to Market Perform and lowers the price target from $17 to $14.5.